TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
November 17, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 17, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 16:01 ET
|
TFF Pharmaceuticals, Inc.
Clinical Proof-of-Concept Demonstrated in Compassionate Use in Two Case Studies with Voriconazole Inhalation Powder (TFF VORI) Growing Body of Peer-Reviewed Scientific Literature Provides...
TFF Pharmaceuticals to Hold Third Quarter 2022 Financial and Business Results Conference Call on November 14, 2022
November 07, 2022 16:05 ET
|
TFF Pharmaceuticals, Inc.
Company conference call and webcast at 4:30 PM ET FORT WORTH, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused...
TFF Pharmaceuticals Announces Collaboration with Aptar Pharma to Explore and Develop Intranasal Delivery of Dry Powder Vaccines and Dry Powder Therapeutics
November 03, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Administration of dry powders will utilize Aptar Pharma’s Unidose (UDS) Powder Nasal Spray System The TFF dry powder vaccines maintain the antigen’s integrity, can be delivered to the targeted region...
TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program
November 01, 2022 16:07 ET
|
TFF Pharmaceuticals, Inc.
Marks the Second Patient to Clinically Benefit from Administration of Voriconazole Inhalation Powder (TFF VORI) Using Thin Film Freezing-Based Technology Positive Results from First Patient Treated...
TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Clinical Programs
November 01, 2022 16:05 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Nov. 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
October 11, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
September 26, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting
September 22, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Two Abstracts Selected for Presentation as part of the Meeting’s Special Poster Collections Research Focuses on the Use of Thin Film Freezing to Produce Dry Powder Inhaled Formulations of...
TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at the 15th International Congress on Lung Transplantation
September 08, 2022 08:00 ET
|
TFF Pharmaceuticals, Inc.
Dr. Bradley Gardiner from the Royal Alfred Hospital in Melbourne, Australia presented results from compassionate use of treating pulmonary fungal infections in a lung transplant patient Patient...